155 related articles for article (PubMed ID: 28867603)
1. Molecular Signatures for Tumor Classification: An Analysis of The Cancer Genome Atlas Data.
Mamatjan Y; Agnihotri S; Goldenberg A; Tonge P; Mansouri S; Zadeh G; Aldape K
J Mol Diagn; 2017 Nov; 19(6):881-891. PubMed ID: 28867603
[TBL] [Abstract][Full Text] [Related]
2. Identifying molecular subtypes in human colon cancer using gene expression and DNA methylation microarray data.
Ren Z; Wang W; Li J
Int J Oncol; 2016 Feb; 48(2):690-702. PubMed ID: 26647925
[TBL] [Abstract][Full Text] [Related]
3. Tree-based machine learning algorithms identified minimal set of miRNA biomarkers for breast cancer diagnosis and molecular subtyping.
Sherafatian M
Gene; 2018 Nov; 677():111-118. PubMed ID: 30055304
[TBL] [Abstract][Full Text] [Related]
4. Integrated genomic analysis for prediction of survival for patients with liver cancer using The Cancer Genome Atlas.
Song YZ; Li X; Li W; Wang Z; Li K; Xie FL; Zhang F
World J Gastroenterol; 2018 Jul; 24(28):3145-3154. PubMed ID: 30065560
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive genomic pan-cancer classification using The Cancer Genome Atlas gene expression data.
Li Y; Kang K; Krahn JM; Croutwater N; Lee K; Umbach DM; Li L
BMC Genomics; 2017 Jul; 18(1):508. PubMed ID: 28673244
[TBL] [Abstract][Full Text] [Related]
6. Integrated Multiple "-omics" Data Reveal Subtypes of Hepatocellular Carcinoma.
Liu G; Dong C; Liu L
PLoS One; 2016; 11(11):e0165457. PubMed ID: 27806083
[TBL] [Abstract][Full Text] [Related]
7. Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling.
Li D; Xia H; Li ZY; Hua L; Li L
Biomed Res Int; 2015; 2015():746970. PubMed ID: 25961039
[TBL] [Abstract][Full Text] [Related]
8. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer.
Zhang Y; Sui J; Shen X; Li C; Yao W; Hong W; Peng H; Pu Y; Yin L; Liang G
Oncol Rep; 2017 Jun; 37(6):3543-3553. PubMed ID: 28498428
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer identification of clinically relevant genomic subtypes using outcome-weighted integrative clustering.
Arora A; Olshen AB; Seshan VE; Shen R
Genome Med; 2020 Dec; 12(1):110. PubMed ID: 33272320
[TBL] [Abstract][Full Text] [Related]
10. The molecular basis of breast cancer pathological phenotypes.
Heng YJ; Lester SC; Tse GM; Factor RE; Allison KH; Collins LC; Chen YY; Jensen KC; Johnson NB; Jeong JC; Punjabi R; Shin SJ; Singh K; Krings G; Eberhard DA; Tan PH; Korski K; Waldman FM; Gutman DA; Sanders M; Reis-Filho JS; Flanagan SR; Gendoo DM; Chen GM; Haibe-Kains B; Ciriello G; Hoadley KA; Perou CM; Beck AH
J Pathol; 2017 Feb; 241(3):375-391. PubMed ID: 27861902
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide analysis of microRNA and mRNA expression signatures in cancer.
Li MH; Fu SB; Xiao HS
Acta Pharmacol Sin; 2015 Oct; 36(10):1200-11. PubMed ID: 26299954
[TBL] [Abstract][Full Text] [Related]
12. Co-localized genomic regulation of miRNA and mRNA via DNA methylation affects survival in multiple tumor types.
Doecke JD; Wang Y; Baggerly K
Cancer Genet; 2016 Oct; 209(10):463-473. PubMed ID: 27810075
[TBL] [Abstract][Full Text] [Related]
13. scan_tcga tools for integrated epigenomic and transcriptomic analysis of tumor subgroups.
Chatterjee A; Stockwell PA; Rodger EJ; Parry MF; Eccles MR
Epigenomics; 2016 Oct; 8(10):1315-1330. PubMed ID: 27625317
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
[TBL] [Abstract][Full Text] [Related]
15. Methylation signature genes identification of cancers occurrence and pattern recognition.
Wang X; Shang W; Li X; Chang Y
Comput Biol Chem; 2020 Apr; 85():107198. PubMed ID: 32120302
[TBL] [Abstract][Full Text] [Related]
16. RNA-Seq accurately identifies cancer biomarker signatures to distinguish tissue of origin.
Wei IH; Shi Y; Jiang H; Kumar-Sinha C; Chinnaiyan AM
Neoplasia; 2014 Nov; 16(11):918-27. PubMed ID: 25425966
[TBL] [Abstract][Full Text] [Related]
17. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of data discretization methods to derive platform independent isoform expression signatures for multi-class tumor subtyping.
Jung S; Bi Y; Davuluri RV
BMC Genomics; 2015; 16 Suppl 11(Suppl 11):S3. PubMed ID: 26576613
[TBL] [Abstract][Full Text] [Related]
19. Minimalist approaches to cancer tissue-of-origin classification by DNA methylation.
Xia D; Leon AJ; Cabanero M; Pugh TJ; Tsao MS; Rath P; Siu LL; Yu C; Bedard PL; Shepherd FA; Zadeh G; Chetty R; Aldape K
Mod Pathol; 2020 Oct; 33(10):1874-1888. PubMed ID: 32415265
[TBL] [Abstract][Full Text] [Related]
20. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
